{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:23:44Z","timestamp":1785507824214,"version":"3.56.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,10,9]],"date-time":"2010-10-09T00:00:00Z","timestamp":1286582400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s00198-010-1424-x","type":"journal-article","created":{"date-parts":[[2010,10,13]],"date-time":"2010-10-13T14:53:26Z","timestamp":1286981606000},"page":"967-982","source":"Crossref","is-referenced-by-count":101,"title":["Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis"],"prefix":"10.1007","volume":"22","author":[{"given":"B.","family":"J\u00f6nsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Str\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Eisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Papaioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. S.","family":"Siris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tosteson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Kanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,10,9]]},"reference":[{"key":"1424_CR1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00198-004-1811-2","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Johnell O (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:229\u2013238","journal-title":"Osteoporos Int"},{"key":"1424_CR2","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)08827-X","volume":"359","author":"PD Delmas","year":"2002","unstructured":"Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359:2018\u20132026","journal-title":"Lancet"},{"key":"1424_CR3","first-page":"9","volume":"23","author":"RK Murthy","year":"2009","unstructured":"Murthy RK, Morrow PK, Theriault RL (2009) Bone biology and the role of the RANK ligand pathway. Oncology (Williston Park) 23:9\u201315","journal-title":"Oncology (Williston Park)"},{"key":"1424_CR4","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"1424_CR5","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"ES Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013\u20131022","journal-title":"Mayo Clin Proc"},{"key":"1424_CR6","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s00198-003-1431-2","volume":"14","author":"A Papaioannou","year":"2003","unstructured":"Papaioannou A, Ioannidis G, Adachi JD, Sebaldt RJ, Ferko N, Puglia M, Brown J, Tenenhouse A, Olszynski WP, Boulos P, Hanley DA, Josse R, Murray TM, Petrie A, Goldsmith CH (2003) Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14:808\u2013813","journal-title":"Osteoporos Int"},{"key":"1424_CR7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00198-008-0644-9","volume":"20","author":"O Strom","year":"2009","unstructured":"Strom O, Borgstrom F, Kanis JA, Jonsson B (2009) Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20:23\u201334","journal-title":"Osteoporos Int"},{"key":"1424_CR8","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00198-007-0349-5","volume":"18","author":"O Strom","year":"2007","unstructured":"Strom O, Borgstrom F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries\u2013an economic evaluation based on the fracture intervention trial. Osteoporos Int 18:1047\u20131061","journal-title":"Osteoporos Int"},{"key":"1424_CR9","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00198-006-0193-z","volume":"17","author":"F Borgstrom","year":"2006","unstructured":"Borgstrom F, Jonsson B, Strom O, Kanis JA (2006) An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int 17:1781\u20131793","journal-title":"Osteoporos Int"},{"key":"1424_CR10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bone.2007.10.019","volume":"42","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Adams J, Borgstrom F, Cooper C, Jonsson B, Preedy D, Selby P, Compston J (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4\u201315","journal-title":"Bone"},{"key":"1424_CR11","doi-asserted-by":"crossref","unstructured":"Landfeldt E, Borgstr\u00f6m F, Robbins S, Str\u00f6m O (2009) A retrospective cohort study of medication adherence to treatment of osteoporosis in a Swedish population. Oral presentation, ISPOR, Paris","DOI":"10.1016\/S1098-3015(10)74079-1"},{"key":"1424_CR12","unstructured":"Kanis J (2008) Assessment of osteoporosis at the primary health-care level. Technical Report, p61, WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK"},{"key":"1424_CR13","unstructured":"Medical products agency (2007) Behandling av osteoporos. www.mpa.se"},{"key":"1424_CR14","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1359\/jbmr.2002.17.4.716","volume":"17","author":"D Felsenberg","year":"2002","unstructured":"Felsenberg D, Silman A, Lunt M, Ambrecht G, Ismail A (2002) Incidence of vertebral fracture in Europe: results from the European prospective osteoporosis study (EPOS). J Bone Miner Res 17:716\u2013724","journal-title":"J Bone Miner Res"},{"key":"1424_CR15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00198-002-1316-9","volume":"14","author":"R Hasserius","year":"2003","unstructured":"Hasserius R, Karlsson MK, Nilsson BE, Redlund-Johnell I, Johnell O (2003) Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int 14:61\u201368","journal-title":"Osteoporos Int"},{"key":"1424_CR16","unstructured":"NICE (2008) Systematic reviews of clinical effectiveness prepared for the guideline Osteoporosis: \u201cAssessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk\u201d. ( http:\/\/wwwniceorguk\/guidance\/indexjsp?action=byID&o=11621 )"},{"key":"1424_CR17","unstructured":"Jones ML, Wilkinson A (2006) Adverse effects and persistence with therapy in patients taking oral alendronate, etidronate or residronate: systematic reviews (NICE). The University of Sheffield, School of Health and Related Research ( http:\/\/www.nice.org.uk\/guidance\/index.jsp?action=download&o=36718 )"},{"key":"1424_CR18","unstructured":"Stevenson M, Davis S (2006) DSU economic evaluation of pooled alendronate and risedronate compared with strontium ranelate, raloxifene, etidronate and teriparatide. National Institute of Clinical Exelence (NICE), http:\/\/www.nice.org.uk\/page.aspx?o=370643 . Accessed 13 May 2009"},{"key":"1424_CR19","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.bone.2009.08.004","volume":"45","author":"JY Reginster","year":"2009","unstructured":"Reginster JY, Bruyere O, Sawicki A, Roces-Varela A, Fardellone P, Roberts A, Devogelaer JP (2009) Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8\u00a0years. Bone 45:1059\u20131064","journal-title":"Bone"},{"key":"1424_CR20","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.4065\/82.12.1493","volume":"82","author":"P Kothawala","year":"2007","unstructured":"Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493\u20131501","journal-title":"Mayo Clin Proc"},{"key":"1424_CR21","unstructured":"McClung M, Freemantle N, Kendler D, Lillestol M, Moffett A, Satram-Hoang S, Yang Y, Kaur P, Macarios D, Siddhanti S (2010) Open-label study to evaluate the adherence, preference, and satisfaction of denosumab and alendronate in postmenopausal women. S 386 Osteoporos Int 21:[Suppl1]S25-S388 1\u00a0C P899"},{"key":"1424_CR22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00198-004-1688-0","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, Jonsson B (2005) Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 16:15\u201325","journal-title":"Osteoporos Int"},{"key":"1424_CR23","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/PL00004173","volume":"11","author":"JA Kanis","year":"2000","unstructured":"Kanis JA, Johnell O, Oden A, Jonsson B, Dawson A, Dere W (2000) Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 11:120\u2013127","journal-title":"Osteoporos Int"},{"key":"1424_CR24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/bmj.315.7102.221","volume":"315","author":"CE Laet De","year":"1997","unstructured":"De Laet CE, van Hout BA, Burger H, Hofman A, Pols HA (1997) Bone density and risk of hip fracture in men and women: cross sectional analysis. Br Med J 315:221\u2013225","journal-title":"Br Med J"},{"key":"1424_CR25","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1359\/JBMR.050304","volume":"20","author":"O Johnell","year":"2005","unstructured":"Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ 3rd, O'Neill T, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185\u20131194","journal-title":"J Bone Miner Res"},{"key":"1424_CR26","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","volume":"15","author":"CM Klotzbuecher","year":"2000","unstructured":"Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721\u2013739","journal-title":"J Bone Miner Res"},{"key":"1424_CR27","unstructured":"Average Exchange Rates. http:\/\/www.riksbank.com Accessed 18 October 2009"},{"key":"1424_CR28","unstructured":"Dental and Pharmaceutical Benefits Agency (2003) General guidelines for economic evaluations from the Pharmaceutical Benefits Board. www.tlv.se"},{"key":"1424_CR29","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00198-005-0015-8","volume":"17","author":"F Borgstrom","year":"2006","unstructured":"Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Lunsjo K, Thorngren KG, Sernbo I, Rehnberg C, Jonsson B (2006) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 17:637\u2013650","journal-title":"Osteoporos Int"},{"key":"1424_CR30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/17453670710015094","volume":"79","author":"O Str\u00f6m","year":"2008","unstructured":"Str\u00f6m O, Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Ceder L, Thorngren KG, Sernbo I, Jonsson B (2008) Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop 79:269\u2013280","journal-title":"Acta Orthop"},{"key":"1424_CR31","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s001980170112","volume":"12","author":"JA Kanis","year":"2001","unstructured":"Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417\u2013427","journal-title":"Osteoporos Int"},{"key":"1424_CR32","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s001980070064","volume":"11","author":"JA Kanis","year":"2000","unstructured":"Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669\u2013674","journal-title":"Osteoporos Int"},{"key":"1424_CR33","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/BF01623315","volume":"5","author":"B Jonsson","year":"1995","unstructured":"Jonsson B, Christiansen C, Johnell O, Hedbrandt J (1995) Cost-effectiveness of fracture prevention in established osteoporosis. Osteoporos Int 5:136\u2013142","journal-title":"Osteoporos Int"},{"key":"1424_CR34","unstructured":"Ekman M (2002) Consumption and production by age in Sweden: Basic facts and health economic implications. http:\/\/www.tlv.se\/Upload\/Foretag\/FOR-040506-tabell-lakemedel.pdf , Accessed 2009-12-11"},{"key":"1424_CR35","doi-asserted-by":"crossref","unstructured":"Johanesson M, Jonsson B, Jonsson L, Kobelt G, Zethraeus N (2009) Why should economic evaluations of medical innovations have a societal perspective? Office of healt economics (OHE) No. 51 October","DOI":"10.2139\/ssrn.2640123"},{"key":"1424_CR36","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1023\/A:1013171831202","volume":"10","author":"K Burstrom","year":"2001","unstructured":"Burstrom K, Johannesson M, Diderichsen F (2001) Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 10:621\u2013635","journal-title":"Qual Life Res"},{"key":"1424_CR37","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35:1095\u20131108","journal-title":"Med Care"},{"key":"1424_CR38","unstructured":"Statistics Sweden http:\/\/www.ssd.scb.se\/databaser\/makro\/Produkt.asp?produktid=BE0101 , Accessed 2010-03-16"},{"key":"1424_CR39","unstructured":"The National Board of Health and Welfare. National Patient Register (NPC) and Cause of Death Register (CDR). http:\/\/www.sos.se\/epc\/epceng.htm"},{"key":"1424_CR40","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1503\/cmaj.081720","volume":"181","author":"G Ioannidis","year":"2009","unstructured":"Ioannidis G, Papaioannou A, Hopman WM, Akhtar-Danesh N, Anastassiades T, Pickard L, Kennedy CC, Prior JC, Olszynski WP, Davison KS, Goltzman D, Thabane L, Gafni A, Papadimitropoulos EA, Brown JP, Josse RG, Hanley DA, Adachi JD (2009) Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. Cmaj 181:265\u2013271","journal-title":"Cmaj"},{"key":"1424_CR41","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","volume":"353","author":"JR Center","year":"1999","unstructured":"Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878\u2013882","journal-title":"Lancet"},{"key":"1424_CR42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00198-003-1490-4","volume":"15","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38\u201342","journal-title":"Osteoporos Int"},{"key":"1424_CR43","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00198-003-1494-0","volume":"14","author":"JA Barrett","year":"2003","unstructured":"Barrett JA, Baron JA, Beach ML (2003) Mortality and pulmonary embolism after fracture in the elderly. Osteoporos Int 14:889\u2013894","journal-title":"Osteoporos Int"},{"key":"1424_CR44","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00198-003-1516-y","volume":"15","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15:108\u2013112","journal-title":"Osteoporos Int"},{"key":"1424_CR45","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.2009.50","volume":"301","author":"D Bliuc","year":"2009","unstructured":"Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. Jama 301:513\u2013521","journal-title":"Jama"},{"key":"1424_CR46","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","volume":"32","author":"JA Kanis","year":"2003","unstructured":"Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468\u2013473","journal-title":"Bone"},{"key":"1424_CR47","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. Jama 280:2077\u20132082","journal-title":"Jama"},{"key":"1424_CR48","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"1424_CR49","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333\u2013340","journal-title":"N Engl J Med"},{"key":"1424_CR50","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00198-008-0786-9","volume":"20","author":"EV McCloskey","year":"2009","unstructured":"McCloskey EV, Johansson H, Oden A, Vasireddy S, Kayan K, Pande K, Jalava T, Kanis JA (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy\u2013additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20:811\u2013817","journal-title":"Osteoporos Int"},{"key":"1424_CR51","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bone.2009.02.014","volume":"44","author":"JA Kanis","year":"2009","unstructured":"Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44:1049\u20131054","journal-title":"Bone"},{"key":"1424_CR52","unstructured":"V\u00e4gverket (1997) V\u00e4gverkets samh\u00e4llsekonomiska kalkymodell. Ekonomisk teori och v\u00e4rderingar. In Authority VSR (ed). Stockholm"},{"key":"1424_CR53","first-page":"605","volume":"14","author":"AN Tosteson","year":"2008","unstructured":"Tosteson AN, Burge RT, Marshall DA, Lindsay R (2008) Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care 14:605\u2013615","journal-title":"Am J Manag Care"},{"key":"1424_CR54","doi-asserted-by":"crossref","unstructured":"Tosteson AN, Do TP, Wade SW, Anthony MS, Downs RW (2010) Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US. Osteoporos Int (E-pub ahead of print)","DOI":"10.1007\/s00198-009-1133-5"},{"key":"1424_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11070","volume":"11","author":"JA Kanis","year":"2007","unstructured":"Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11:1\u2013256","journal-title":"Health Technol Assess"},{"key":"1424_CR56","unstructured":"Stevenson M, Davies S (2006) DSU economic evaluation of pooled alendronate and risedronate compared with strontium ranelate, raloxifene, etidronate and teriparatide( http:\/\/guidance.nice.org.uk\/page.aspx?o=370643 )"},{"key":"1424_CR57","doi-asserted-by":"crossref","unstructured":"Str\u00f6m O, Landfeldt E, Robbins S, Borgstr\u00f6m F (2010) Adherence to treatment of osteoporosis and fracture risk: The Swedish Adherence Register Analysis (SARA). Oral presentation\/poster ECCEO\/IOF, Florence","DOI":"10.1007\/s00198-011-1549-6"},{"key":"1424_CR58","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.bone.2005.10.022","volume":"38","author":"KF Huybrechts","year":"2006","unstructured":"Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922\u2013928","journal-title":"Bone"},{"issue":"suppl 1","key":"1424_CR59","first-page":"S282","volume":"20","author":"E McCloskey","year":"2005","unstructured":"McCloskey E, De Takats D, Orgee J, Aropinn S, Jalava T, Cliffe J, Reaney L, McGurk C, Charlesworth DJAK (2005) Characteristics associated with non-persistence during daily therapy. Experience from the placebo wing of a community based clinical trial. J Bone Miner Res 20(suppl 1):S282","journal-title":"J Bone Miner Res"},{"key":"1424_CR60","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s001980050215","volume":"10","author":"B Jonsson","year":"1999","unstructured":"Jonsson B, Kanis J, Dawson A, Oden A, Johnell O (1999) Effect and offset of effect of treatments for hip fracture on health outcomes. Osteoporos Int 10:193\u2013199","journal-title":"Osteoporos Int"},{"key":"1424_CR61","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s001980200106","volume":"13","author":"JA Kanis","year":"2002","unstructured":"Kanis JA, Jonsson B (2002) Economic evaluation of interventions for osteoporosis. Osteoporos Int 13:765\u2013767","journal-title":"Osteoporos Int"},{"key":"1424_CR62","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1007\/s00198-004-1643-0","volume":"15","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Borgstrom F, Johnell O, Jonsson B (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15:862\u2013871","journal-title":"Osteoporos Int"},{"key":"1424_CR63","unstructured":"WHO (1998) Guidelines for preclinical evaluation and clinical trials in osteoporosis. Geneve. http:\/\/whqlibdoc.who.int\/publications\/1998\/9241545224_eng.pdf , Accessed"},{"key":"1424_CR64","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1359\/JBMR.050501","volume":"20","author":"R Prince","year":"2005","unstructured":"Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH (2005) Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20:1507\u20131513","journal-title":"J Bone Miner Res"},{"key":"1424_CR65","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/archinte.162.6.665","volume":"162","author":"GA Greendale","year":"2002","unstructured":"Greendale GA, Espeland M, Slone S, Marcus R, Barrett-Connor E (2002) Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen\/Progestin Interventions (PEPI) Safety Follow-up Study. Arch Intern Med 162:665\u2013672","journal-title":"Arch Intern Med"},{"key":"1424_CR66","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.bone.2003.12.021","volume":"34","author":"YZ Bagger","year":"2004","unstructured":"Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Mollgaard A, Ravn P, Qvist P, Kanis JA, Christiansen C (2004) Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 34:728\u2013735","journal-title":"Bone"},{"key":"1424_CR67","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(81)91848-1","volume":"1","author":"C Christiansen","year":"1981","unstructured":"Christiansen C, Christensen MS, Transbol I (1981) Bone mass in postmenopausal women after withdrawal of oestrogen\/gestagen replacement therapy. Lancet 1:459\u2013461","journal-title":"Lancet"},{"key":"1424_CR68","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7326\/0003-4819-122-1-199501010-00002","volume":"122","author":"JA Cauley","year":"1995","unstructured":"Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR (1995) Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 122:9\u201316","journal-title":"Ann Intern Med"},{"key":"1424_CR69","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1001\/jama.291.18.2212","volume":"291","author":"E Banks","year":"2004","unstructured":"Banks E, Beral V, Reeves G, Balkwill A, Barnes I (2004) Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. Jama 291:2212\u20132220","journal-title":"Jama"},{"key":"1424_CR70","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR (2006) Effects of continuing or stopping alendronate after 5\u00a0years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. Jama 296:2927\u20132938","journal-title":"Jama"},{"key":"1424_CR71","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1359\/jbmr.080510","volume":"23","author":"AM Gallagher","year":"2008","unstructured":"Gallagher AM, Rietbrock S, Olson M, van Staa TP (2008) Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 23:1569\u20131575","journal-title":"J Bone Miner Res"},{"key":"1424_CR72","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00198-008-0604-4","volume":"19","author":"JR Curtis","year":"2008","unstructured":"Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG (2008) Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 19:1613\u20131620","journal-title":"Osteoporos Int"},{"key":"1424_CR73","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.bone.2007.09.059","volume":"42","author":"I Lekander","year":"2008","unstructured":"Lekander I, Borgstrom F, Strom O, Zethraeus N, Kanis JA (2008) Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK-Results based on the Women's Health Initiative randomised controlled trial. Bone 42:294\u2013306","journal-title":"Bone"},{"key":"1424_CR74","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1017\/S0266462305050609","volume":"21","author":"N Zethraeus","year":"2005","unstructured":"Zethraeus N, Borgstrom F, Jonsson B, Kanis J (2005) Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial. Int J Technol Assess Health Care 21:433\u2013441","journal-title":"Int J Technol Assess Health Care"},{"key":"1424_CR75","unstructured":"NICE (2008) Osteoporosis\u2014secondary prevention including strontium ranelate: Appraisal consultation document. www.nice.org.uk"},{"key":"1424_CR76","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00019053-200422170-00005","volume":"22","author":"F Borgstrom","year":"2004","unstructured":"Borgstrom F, Johnell O, Kanis JA, Oden A, Sykes D, Jonsson B (2004) Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 22:1153\u20131165","journal-title":"Pharmacoeconomics"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-010-1424-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-010-1424-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-010-1424-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T08:46:43Z","timestamp":1559724403000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-010-1424-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,9]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["1424"],"URL":"https:\/\/doi.org\/10.1007\/s00198-010-1424-x","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,9]]}}}